Pacific Biosciences of California (PACB) Environmental, Social & Governance (ESG) Data

Company Profile

Search within these filings

View filings

Exhibits within filings

Filing insights

Export filings list

Export a CSV file of filings or unique filing companies (up to first 5,000 results).

Download list of filings Download list of companies

External links

Employees

Data from SEC filings

Employee count

CEO pay ratio

CEO Salary

Median Employee Salary

ESG framework mentions

In last year of SEC filings

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Agriculture Biodiversity Circular Climate Conflict Minerals Ecosystem Environment Environmental Extraction Life Cycle Lifecycle Materials Mineral Natural Resources Nature Offset Package Pandemic Raw Materials Recycling Waste Access African American Asian Benefits Black California Consumer Privacy Act Citizenship Collective Bargaining Community Culture Customer Cyber Cybersecurity Data Privacy Data Security Death Demographic Disability Diversity Employee Employee Retention Engagement Ethnicity Gender General Data Protection Regulation Health and Safety Health Care Healthcare Hire Hiring Hispanic Human Capital Human Resources Incident Injury Latinx LGBTQ Parental Leave Pay for Performance Perquisites Privacy Product Quality Recall Recruit Recruitment Reimbursement Retention Safety Satisfaction Skill Skilled Skills Social Society Stakeholder Supplier Supply Chain Supply Chain Management Talent Training Union Workers Workforce Anti-corruption Antitrust Assessment Assurance Attorneys General Audit Board Oversight Bonus Bribery Classified Classified Board Claw Back Clawback Commitment Corporate Governance Corporate Purpose Corruption Department of ESG Ethics Executive Compensation Expert Fraud Goals Governance Hedging Incentive Incentivize Independence Independent Independent Chair Innovate Innovation Innovative Investigation Lawsuit Lead Independent Director Leadership Litigation Long-term Majority Mission Oversee Oversight Perquisite Pledging Procurement Purpose R&D Reputation Reputational Research and Development Responsibility Responsible Special Meeting Stewardship Strategy Sustainability Sustainable Targets Tax Tenure Transparency Voting Rights

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

Pacific Biosciences of California, Inc. (the “Company”) held its 2023 annual meeting of stockholders (the “Annual Meeting”) on May 24, 2023. Of the 249,810,685 shares of the Company’s common stock outstanding as of 5:00 p.m. (Pacific time) on April 5, 2023, the record date for the Annual Meeting, 219,666,084 shares were represented at the Annual Meeting, either by virtual attendance or by proxy, constituting approximately 87.93% of shares of common stock entitled to vote at the Annual Meeting. The five matters voted on at the Annual Meeting and the voting results with respect to each such matter are set forth below:
Proposal 1: Election of Three Class I Directors

Name of Director	For	Against	Abstain	Broker Non-Votes

Christian O. Henry	189,711,865	3,089,347	58,199	26,806,673
John F. Milligan, Ph.D.	190,066,819	2,674,761	117,831	26,806,673
Lucy Shapiro, Ph.D.	178,044,672	14,703,637	111,102	26,806,673

Each director nominee was duly elected to serve until the 2026 annual meeting of stockholders and until his or her successor is duly elected and qualified, subject to his or her earlier resignation or removal.
Proposal 2: Ratification of the Appointment of Independent Registered Public Accounting Firm

For						Against						Abstain						Broker Non-Votes

218,312,891						622,576						730,617						-

The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
Proposal 3: Advisory Vote to Approve Named Executive Officer Compensation.

For						Against						Abstain						Broker Non-Votes

178,087,666						14,553,090						218,655						26,806,673

The stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers.
Proposal 4: Advisory Vote to Approve the Frequency of Future Advisory Votes on Named Executive Officer Compensation


Every 1 Year	Every 2 Years	Every 3 Years	Abstain	Broker Non-Votes
134,152,334	238,320	58,328,847	139,910	26,806,673

Based on the votes set forth above, the stockholders advised that they were in favor of every one year as the frequency of holding an advisory vote on the compensation of named executive officers. In accordance with the voting results for this proposal, the Company has determined to hold future advisory votes on the compensation of the Company’s named executive officers every one year until the next required non-binding advisory vote on the frequency of future advisory votes regarding named executive officer compensation. The next required advisory vote on the frequency of future advisory votes on the compensation of the Company’s named executive officers will take place no later than at the Company’s 2029 annual meeting of stockholders.

Proposal 5: Advisory Vote to Approve the Retention of the Classified Structure of the Corporation’s Board

For						Against						Abstain						Broker Non-Votes

32,282,459						136,324,990						24,251,959						26,806,676

The stockholders, on a non-binding advisory basis, voted against retaining the Company’s classified board of directors.